Pre-made Zolbetuximab benchmark antibody ( Whole mAb, anti-CLDN18 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-648

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-648 Category Tag

Product Details

Pre-made Zolbetuximab benchmark antibody (Whole mAb, anti-CLDN18 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]

Products Name (INN Index)

Pre-Made Zimberelimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody

INN Name

Zimberelimab

Target

PDCD1

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Lambda

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2020

Companies

Harbin Gloria Pharmaceuticals,WuXi Biologics,Arcus Biosciences,Beijing Cancer Hospital,Guangzhou Gloria Biosciences,Strata Oncology

Conditions Approved

Hodgkin's disease

Conditions Active

Cervical cancer,Non-small cell lung cancer,Breast cancer,Cancer,Ovarian cancer,Pancreatic cancer,Solid tumours

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

PDCD1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide